COMPARATIVE-STUDIES ON THE AFFINITIES OF ATP DERIVATIVES FOR P-2X-PURINOCEPTORS IN RAT URINARY-BLADDER

被引:56
作者
BO, XN
FISCHER, B
MAILLARD, M
JACOBSON, KA
BURNSTOCK, G
机构
[1] UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND
[2] UNIV LONDON UNIV COLL,CTR NEUROSCI,LONDON WC1E 6BT,ENGLAND
[3] NIDDK,BIOORGAN CHEM LAB,BETHESDA,MD 20892
关键词
P-2X-PURINOCEPTORS; URINARY BLADDER; H-3; ALPHA; BETA-METHYLENE ATP; ATP DERIVATIVES; SURAMIN; REACTIVE BLUE 2; PPADS; RADIOLIGAND BINDING ASSAY;
D O I
10.1111/j.1476-5381.1994.tb13204.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Radioligand binding assays have been used to determine the affinities of a series of ATP derivatives with modifications of the polyphosphate chain, adenine and ribose moieties of the ATP molecule for [H-3]-alpha,beta-methylene ATP ([H-3]-alpha,beta-MeATP) binding sites in rat urinary bladder. 2 The replacement of the bridging oxygen in the triphosphate chain of ATP (pIC(50) = 5.58) with a methylene or imido group markedly increased the affinity (691 fold in IC50 values for beta,gamma-imidoATP, 15 fold for beta,gamma-methylene ATP), and the replacement of an ionized oxygen on the gamma-phosphate with a sulphur (ATP gamma S) also led to increased affinity (5623 fold in IC50 values). 3 Modifications at N-6, N-1, and C-8 positions on the purine base usually reduced the affinity of ATP (a decrease of 2.8 fold in IC50 values for N-6-methylATP and 8.9 fold for 8-bromo ATP), while the attachment of an alkylthio group to the C-2 position greatly increased the affinity for P-2X-purinoceptors (from 3.5 to 98 fold increase in IC50 values). 4 Replacement of the 3'-hydroxyl group on the ribose with substituted amino or acylamino groups produced more potent P-2X-purinoceptor agonists (an increase of 447 fold in IC50 values for 3'-deoxy-3'-benzylamino ATP and 28 fold for 3'-deoxy-3'-(4-hydroxyphenylpropionyl)amino ATP. 5 Diadenosine polyphosphates (Ap[n]A) were also shown to displace the [H-3]-alpha,beta-MeATP binding. The rank order of potency was Ap6A > Ap5A > Ap4A >> Ap3A >> Ap2A. 6 Suramin, PPADS, and reactive blue 2 could competitively displace the binding of [H-3]-alpha,beta-MeATP to P-2X-purinoceptors, with pIC(50) values of 6.26, 5.35, and 6.22, respectively.
引用
收藏
页码:1151 / 1159
页数:9
相关论文
共 52 条
[1]   PURINOCEPTOR NOMENCLATURE - A STATUS-REPORT [J].
ABBRACCHIO, MP ;
CATTABENI, F ;
FREDHOLM, BB ;
WILLIAMS, M .
DRUG DEVELOPMENT RESEARCH, 1993, 28 (03) :207-213
[2]   HIGH-AFFINITY AND LOW-AFFINITY BINDING-SITES FOR [H-3] ALPHA,BETA-METHYLENE ATP IN RAT URINARY-BLADDER MEMBRANES [J].
BO, X ;
BURNSTOCK, G .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 101 (02) :291-296
[3]   HETEROGENEOUS DISTRIBUTION OF [H-3] ALPHA,BETA-METHYLENE ATP BINDING-SITES IN BLOOD-VESSELS [J].
BO, XN ;
BURNSTOCK, G .
JOURNAL OF VASCULAR RESEARCH, 1993, 30 (02) :87-101
[4]   TRIPHOSPHATE, THE KEY STRUCTURE OF THE ATP MOLECULE RESPONSIBLE FOR INTERACTION WITH P(2X)-PURINOCEPTORS [J].
BO, XN ;
BURNSTOCK, G .
GENERAL PHARMACOLOGY, 1993, 24 (03) :637-640
[5]   EFFECTS OF ADENOSINE 5'-TRIPHOSPHATE (ATP) AND BETA-GAMMA-METHYLENE ATP ON THE RAT URINARY-BLADDER [J].
BROWN, C ;
BURNSTOCK, G ;
COCKS, T .
BRITISH JOURNAL OF PHARMACOLOGY, 1979, 65 (01) :97-102
[6]  
BRUNS RF, 1980, N-S ARCH PHARMACOL, V315, P5, DOI 10.1007/BF00504224
[7]   STRUCTURE-ACTIVITY-RELATIONSHIPS FOR DERIVATIVES OF ADENOSINE-5'-TRIPHOSPHATE AS AGONISTS AT P-2 PURINOCEPTORS - HETEROGENEITY WITHIN P-2X AND P-2Y SUBTYPES [J].
BURNSTOCK, G ;
FISCHER, B ;
HOYLE, CHV ;
MAILLARD, M ;
ZIGANSHIN, AU ;
BRIZZOLARA, AL ;
VONISAKOVICS, A ;
BOYER, JL ;
HARDEN, TK ;
JACOBSON, KA .
DRUG DEVELOPMENT RESEARCH, 1994, 31 (03) :206-219
[8]   PHYSIOLOGICAL AND PATHOLOGICAL ROLES OF PURINES - AN UPDATE [J].
BURNSTOCK, G .
DRUG DEVELOPMENT RESEARCH, 1993, 28 (03) :195-206
[9]   IS THERE A BASIS FOR DISTINGUISHING 2 TYPES OF P2-PURINOCEPTOR [J].
BURNSTOCK, G ;
KENNEDY, C .
GENERAL PHARMACOLOGY, 1985, 16 (05) :433-440
[10]   STUDIES ON THE STEREOSELECTIVITY OF THE P2-PURINOCEPTOR [J].
BURNSTOCK, G ;
CUSACK, NJ ;
HILLS, JM ;
MACKENZIE, I ;
MEGHJI, P .
BRITISH JOURNAL OF PHARMACOLOGY, 1983, 79 (04) :907-913